5 Must-Read Analyst Questions From Quest’s Q1 Earnings Call
Quest Diagnostics delivered first quarter results that exceeded Wall Street’s revenue and profit expectations, driven by broad-based demand for its clinical innovations and expansion into new areas like end-stage renal disease and brain health. Management attributed the organic growth to increased test volumes across physician, hospital, and consumer channels, alongside productivity gains from automation and artificial intelligence. CEO James Davis highlighted the strong adoption of advanced diagnostics, particularly in Alzheimer’s testing, noting, “Our Alzheimer’s book of testing more than doubled year-over-year.”
Is now the time to buy DGX? Find out in our full research report (it’s free for active Edge members).
Quest (DGX) Q1 CY2026 Highlights:
- Revenue: $2.90 billion vs analyst estimates of $2.82 billion (9.2% year-on-year growth, 2.7% beat)
- Adjusted EPS: $2.50 vs analyst estimates of $2.37 (5.6% beat)
- Adjusted EBITDA: $594 million vs analyst estimates of $537.8 million (20.5% margin, 10.5% beat)
- The company slightly lifted its revenue guidance for the full year to $11.84 billion at the midpoint from $11.76 billion
- Management raised its full-year Adjusted EPS guidance to $10.73 at the midpoint, a 1.2% increase
- Operating Margin: 13.8%, in line with the same quarter last year
- Sales Volumes rose 10.9% year on year (12.4% in the same quarter last year)
- Market Capitalization: $21.77 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Quest’s Q1 Earnings Call
-
Michael Cherny (Leerink Partners) asked about the sustainability of organic volume growth and the impact of partnerships. CFO Sam Samad explained that Fresenius and Corewell contributed 7% to total volume growth, and management expects this trend to remain steady, with test-per-requisition increases driven by advanced diagnostics and consumer wellness.
-
Elizabeth Anderson (Evercore ISI) inquired about weather-related impacts and margin expectations. CEO James Davis responded that while winter storms affected the quarter, 70% of missed appointments were rescheduled, and some negative weather is factored into second-half expectations. Samad clarified that margin cadence should mirror last year with slightly more expense weighting in the second half.
-
Patrick Donnelly (Citi) asked about Project Nova investment timing and potential expense shifts. Samad confirmed the $0.25 EPS impact remains unchanged, but more spending will occur in the second half of the year, with fuel costs and ramping investments all embedded in current guidance.
-
Ann Hynes (Mizuho Securities) probed on organic volume outperformance and ACA subsidy effects. Davis said growth was broad-based across hospital, physician, and consumer channels, and so far, no negative impact from ACA subsidy expirations has been observed, though some caution remains embedded in guidance.
-
Jack Meehan (Nephron) sought clarity on PAMA data submission and Medicare rate outlook. Davis explained Quest is prepared for the new survey, expects broader participation from hospital labs, and hopes the finalized data will support higher rates, depending on legislative developments around the RESULTS Act.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be watching (1) the continued ramp-up and margin improvement in health system partnerships with Corewell and Fresenius, (2) the pace of advanced diagnostic test adoption, especially in Alzheimer’s and cardiometabolic categories, and (3) ongoing growth in consumer testing channels and digital partnerships. Execution on Project Nova and regulatory developments around Medicare pricing are also critical signposts.
Quest currently trades at $197.10, in line with $196.31 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
